B-Cell Lymphoma

The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy.

This will be done by integrating data and samples collected from patients undergoing standard of care treatment for high-grade B cell lymphoma.

The trial is being funded jointly by AstraZeneca and the Cancer Research UK Cambridge Centre as well as being a flagship trial for MFICM. The trial currently has a total of 72 patients recruited over 5 sites as follows:

Addenbrooke’s Hospital                                                          20

University Hospitals Leicester                                                20

Norfolk & Norwich University Hospital                                 19

Northwest Anglia NHS Foundation Trust                             2

Nottingham University Hospital                                             11

Data will be integrated from

1. Clinical risk factors from the International Prognostic Index (IPI)
2. Up-front genomic subtype based on molecular profiling of diagnostic biopsy
3. Serial ctDNA monitoring during treatment.
4. Radiological response imaging

Clinical trial registration